Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure
Original Research | By CK Nagaraju, EL Robinson, KR Sipido et al.
Targeting the Immune System in Atherosclerosis: JACC State-of-the-Art Review
Review Article | By TX Zhao, Z Mallat.
Atherosclerosis has long been known as an inflammatory disease. However, whether targeting inflammation improves outcomes was unproven until the recent results of CANTOS (Canakinumab Anti-InflammatoryThrombosis Outcomes Study). In this review, we reflect on why it has taken a long time to prove the inflammatory hypothesis of atherosclerosis and derive important lessons for the future. In particular, we discuss the...
Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week
Review Article | By F Triposkiadis, A Xanthopoulos, J Butler et al.
Heart failure (HF) is a clinical syndrome that usually develops in the elderly. Complex interactions of the cardiovascular aging process with risk factors (obesity, hypertension, and atherosclerosis), comorbidities (anemia, chronic kidney disease, diabetes, and so on), and disease modifiers (sex, genes, others) contribute to the development of HF phenotype and outcome. A conglomerate of cellular and molecular mechanisms underl...
Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study
Original Research | By R Asleh, M Enriquez-Sarano, AS Jaffe et al.
BACKGROUND - Galectin-3 (Gal-3) is implicated in cardiac fibrosis, but its association with adverse outcomes after myocardial infarction (MI) is unknown. OBJECTIVES - The purpose of this study was to examine the prognostic value of Gal-3 in a community cohort of incident MI. METHODS - A population-based incidence MI cohort was pros...
Mechanisms of Vascular Aging, A Geroscience Perspective JACC Focus Seminar
Review Article | By Z Ungvari, S Tarantini, F Sorond et al.
Age-related pathological alterations of the vasculature have a critical role in morbidity and mortality of older adults. In epidemiological studies, age is the single most important cardiovascular risk factor that dwarfs the impact of traditional risk factors. To develop novel therapeutic interventions for prevention of age-related vascular pathologies, it is crucial to understand the cellular and molecular mechanisms of vascular aging. In this revi...
Biological Versus Chronological Aging: JACC Focus Seminar
Review Article | By MR Hamczyk, RM Nevado, A Barettino et al.
Long-Term Exposure to Fine Particulate Matter and Cardiovascular Disease in China
Original Research | By FC Liang, FC Liu, DF Gu et al.
BACKGROUND - Evidence of the effects of long-term fine particulate matter (PM2.5) exposure on cardiovascular diseases (CVDs) is rare for populations exposed to high levels of PM2.5 in China and in other countries with similarly high levels. OBJECTIVES - The aim of this study was to assess the CVD risks associated with long-term exposure to PM2.5 in China. METHODS...
Cardiovascular Mortality After Type 1 and Type 2 Myocardial Infarction in Young Adults
Original Research | By A Singh, DL Bhatt, R Blankstein et al.
BACKGROUND - Type 2 myocardial infarction (MI) and myocardial injury are associated with increased short-term mortality. However, data regarding long-term mortality are lacking. OBJECTIVES - This study compared long-term mortality among young adults with type 1 MI, type 2 MI, or myocardial injury. METHODS - Adults age 50 years or younger who pres...
Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review
Review Article | By C Yerasi, BC Case, BJ Forrestal et al.
Percutaneous coronary intervention with a drug-eluting stent is the most common mode of revascularization for coronary artery disease. However, restenosis rates remain high. Non-stent-based local drug delivery by a drug-coated balloon (DCB) has been investigated, as it leaves no metallic mesh. A DCB consists of a semicompliant balloon coated with antiproliferative agents encapsulated in a polymer matrix, which is release...